title: The clastogenicity of 4NQO is cell-type dependent and linked to cytotoxicity, length of exposure and p53 proficiency.
abstract: 4-Nitroquinoline 1-oxide (4NQO) is used as a positive control in various genotoxicity assays because of its known mutagenic and carcinogenic properties. The chemical is converted into 4-hydroxyaminoquinoline 1-oxide and gives rise to three main DNA adducts, N-(deoxyguanosin-8-yl)-4AQO, 3-(desoxyguanosin-N (2)-yl)-4AQO and 3-(deoxyadenosin-N (6)-yl)-4AQO. This study was designed to assess the shape of the dose-response curve at low concentrations of 4NQO in three human lymphoblastoid cell lines, MCL-5, AHH-1 and TK6 as well as the mouse lymphoma L5178Y cell line in vitro. Chromosomal damage was investigated using the in vitro micronucleus assay, while further gene mutation and DNA damage studies were carried out using the hypoxanthine-guanine phosphoribosyltransferase forward mutation and comet assays. 4NQO showed little to no significant increases in micronucleus induction in the human lymphoblastoid cell lines, even up to 55±5% toxicity. A dose-response relationship could only be observed in the mouse lymphoma cell line L5178Y after 4NQO treatment, even at concentrations with no reduction in cell viability. Further significant increases in gene mutation and DNA damage induction were observed. Hence, 4NQO is a more effective point mutagen than clastogen, and its suitability as a positive control for genotoxicity testing has to be evaluated for every individual assay.
authors.forename: Katja
authors.initials: K
authors.lastname: Brüsehafer
authors.forename: Bella B
authors.initials: BB
authors.lastname: Manshian
authors.affiliation: Drug Safety and Metabolism, AstraZeneca, Unit 310, Darwin Building, Cambridge Science Park, Milton Road, Cambridge CB40WG, UK.
authors.forename: Ann T
authors.initials: AT
authors.lastname: Doherty
authors.forename: Zoulikha M
authors.initials: ZM
authors.lastname: Zaïr
authors.forename: George E
authors.initials: GE
authors.lastname: Johnson
authors.forename: Shareen H
authors.initials: SH
authors.lastname: Doak
authors.forename: Gareth J S
authors.initials: GJ
authors.lastname: Jenkins
mesh_terms: D015112:4-Nitroquinoline-1-oxide / Q000633:toxicity*; D000818:Animals; D002273:Carcinogens / Q000633:toxicity*; D045744:Cell Line, Tumor; D002869:Chromosome Aberrations / Q000139:chemically induced; D020552:Comet Assay; D004249:DNA Damage / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000235:genetics; D051379:Mice; D015162:Micronucleus Tests; D009152:Mutagenicity Tests; D009153:Mutagens / Q000633:toxicity*; D009154:Mutation / Q000187:drug effects; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D002273:Carcinogens; D009153:Mutagens; D016159:Tumor Suppressor Protein p53; D015112:4-Nitroquinoline-1-oxide; D007041:Hypoxanthine Phosphoribosyltransferase